Moreover, because insulin is the mainstay of treatment for T1D and uncontrolled T2D, and because diabetes patients tend to participate less in mammography screening programs [42, 43], increasing screening awareness and participation among insulin-treated patients with diabetes may be a first step in reducing insulin-associated adverse effects from a clinical perspective. This evidence concerns the gene INS and diabetes mellitus.